Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
A Phase 4 Single Arm Open Label Study for the Efficacy and Safety of Prolia in Treatment of Male Subjects With Osteoporosis in Mainland China
Sponsor: Amgen
A PHASE4 clinical study on Osteoporosis, this trial is ongoing. The trial is conducted by Amgen and has accumulated 12 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE4
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE4
-
Aug 2025 — Oct 2025 [monthly]
Recruiting PHASE4
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE4
▶ Show 7 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE4
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE4
-
Nov 2024 — Apr 2025 [monthly]
Recruiting PHASE4
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Chongqing, China , Guangzhou, China , Harbin, China , Huaian, China , Jinan, China , Nanchang, China , Nanjing, China , Pingxiang, China , Shanghai, China and 2 more locations